We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AngioDynamics (ANGO) Product Line Strong, Debt Level High
Read MoreHide Full Article
On Apr 2, we issued an updated research report on AngioDynamicsInc. (ANGO - Free Report) . The stock has a Zacks Rank #3 (Hold). While a strong portfolio is likely to enhance customer base, high debt levels continue to bother the company.
AngioDynamics’ broad product spectrum lends it a competitive edge in the U.S. MedTech space. In this regard, the company’s flagship NanoKnife platform has been driving growth for its Oncology business. In the just-reported third quarter of fiscal 2018, the platform was a major contributor to revenues as it witnessed mid-teen growth in sales on a year-over-year basis. Earlier, the product had received FDA clearance for the surgical ablation of soft tissue.
AngioDynamics has also provided an innovative series of minimally-invasive medical devices used for vascular access, surgery, peripheral vascular disease and oncology. The portfolio includes ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.
Apart from portfolio strength, the company’s balance sheet continues to show solid cash-flow generation. At the end of the third quarter, AngioDynamics had generated $4.3 million in operating cash flow and $3.9 million in free cash flow.
On the flip side, the company’s third-quarter sales fell by almost 2% on a year-over-year basis. The downside was led by declines in Venous unit, RFA product (radio frequency ablation) and PICCs businesses.
Furthermore, high debt levels continue to plague AngioDynamics. The company ended the third quarter of fiscal 2018 with debt of $93.8 million. The debt level in the second quarter was $95 million. This is likely to impose certain operating and financial restrictions.
Price Performance
In the past year, AngioDynamics’ shares have gained a nominal 2.1%, compared with the industry’s gain of 24.4%. The company is exposed to pricing headwinds stemming from lower selling prices of peripheral vascular products due to aggressive price competition.
athenahealth has an expected long-term growth rate of 17.7% and projected earnings per share growth rate of 21.5%.
Bio-Rad has an expected long-term growth rate of 20% and projected earnings per share growth rate of 20%.
Centene has an expected long-term growth rate of 14.4% and projected earnings per share growth rate of 14.4%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
AngioDynamics (ANGO) Product Line Strong, Debt Level High